Halozyme outlines $1.71B–$1.81B 2026 revenue target as new subcutaneous technologies expand pipeline
Halozyme Therapeutics, Inc. · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $66.54
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS